MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Bruker Corporation
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bruker Announces Acquisition of Scientific Software Provider Arxspan Enhanced Focus on Pharma and Biopharma Software and Workflow Solutions - Bruker Corporation today announced that it has acquired Arxspan LLC, a provider of cloud-based scientific software and workflow solutions, based in Southborough, Massachusetts - Arxspan.com / Bruker.com
Bruker Announces Acquisition of Scientific Software Provider Arxspan Enhanced Focus on Pharma and Biopharma Software and Workflow Solutions

 

NewswireToday - /newswire/ - Billerica, MA, United States, 2019/03/14 - Bruker Corporation today announced that it has acquired Arxspan LLC, a provider of cloud-based scientific software and workflow solutions, based in Southborough, Massachusetts - Arxspan.com / Bruker.com. NASDAQ: BRKR

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Arxspan is known for its line of cloud-based products for the management of research data under the Arxlab® brand. The company has a focus on serving pharmaceutical and biopharma customers. Financial details of the transaction were not disclosed.

Bruker can now provide a range of software tools for customers in the chemistry, pharmaceutical, biopharma and analytical laboratory markets. Together with the Mestrelab strategic partnership and majority investment, the acquisition of Arxspan will allow Bruker to offer state-of-the-art chemistry and biopharma software tools, supporting discovery and development.

Commenting on the acquisition, Dr. Falko Busse, Group President for Bruker Biospin, stated: "The Arxspan acquisition, coupled with our strategic partnership with Mestrelab, positions Bruker firmly in the field of cloud-based, scientific software for our chemistry and pharma customers. Bruker is committed to providing intuitive end-to-end solutions that make analysis and knowledge extraction in scientific research faster and easier. Our new software solutions enable our biopharma customers to increase their productivity in drug discovery and development.

"Peter Rosati, the CEO and a co-founder of Arxspan, commented: "We are excited that Arxspan is now part of a leading global life science tools company. The merger with Bruker will increase our footprint and help us support and grow our increasingly global customer base. We are focused on showing immediate benefits of the merger to our pharma and biopharma customers. Arxspan's proven enterprise SaaS platform will be a solid foundation for Bruker's chemistry and biology informatics offerings."

About Arxspan, LLC

Arxspan, LLC (arxspan.com) was founded in 2011 to deliver cloud-based scientific informatics tools to customers around the globe. That same year, Arxspan's multi-tenant cloud Electronic Laboratory Notebook (ELN) was released to customers in the academia and biotech market place. The ELN was launched with an enterprise-level feature set designed to support small biotech start-ups as well as global pharma. Arxspan released the integrated Registration module in 2013 in collaboration with multiple customers. In 2017, Arxspan released the Workflow module to enable close coordination of compound/biologic request and fulfillment between companies and their external collaborators.

Recently, the Data Publisher was released to simplify the integration of Arxspan and other enterprise, legacy and AI data platforms. Today, Arxspan offers a complete enterprise informatics suite including modules for ELN, Chemical and Biological Registration, Chemical and Biological Inventory and Assay Data Management, with system-wide search and reporting functionality. Arxspan customers/users are based in North America, Asia, India and Europe. Arxspan continues to deploy its world-class platforms, tools, services and best-in-class support to a rapidly growing customer base.

About Bruker Corporation

Bruker (bruker.com) is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.

Investor Relations Contact
Miroslava Minkova, Director, Investor Relations & Corporate Development
T: +1 978-663-3660 x1479
E: miroslava.minkova[.]bruker.com

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Bruker Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bruker Announces Acquisition of Scientific Software Provider Arxspan Enhanced Focus on Pharma and Biopharma Software and Workflow Solutions

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Thorsten Thiel, Ph.D. - Bruker.com 
+49(721) 5161 6500 thorsten.thiel[.]bruker.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bruker Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Bruker Corporation / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Huntington Study Group Ltd

Visit  BizJobs.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)